The trial supported by the Soupy for Loopy Foundation will use bevacizumab (AvastinTM) and zoledronic acid (Zometa®) with low doses of the chemotherapeutic agent cyclophosphamide (cytoxan). Referred as N0702,

Funds will support NANT 2013-02 Phase I Study of Sorafenib with Cyclophosphamide and Topotecan in Patients with Relapsed and Refractory Neuroblastoma. 

2008   $25,000

NANT Grants for Neuroblastoma Research

New Approaches to Neuroblastoma Therapy (NANT)

2014   $44,907

Soupy for Loopy is a GuideStar Exchange Gold Participant